Beta-3 agonists for overactive bladder
Mirabegron and vibegron for overactive bladder.
Key point
Vibegron appears to rank more favourably for urgency, urgency incontinence and maximum voided volume, while mirabegron ranks more favourably for 24-hour frequency.
From: Comparing the safety and efficacy of vibegron, mirabegron and tolterodine in patients with overactive bladder: a systematic review and network meta-analysis (Eur J Obstet Gynecol Reprod Biol, 2026 Sep) ↗Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 11, 19, 11, 12, 15.
All papers from the last 12 months
112 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Real-world outcomes of tadalafil plus mirabegron combination therapy in men with lower urinary tract symptoms and overactive bladder symptoms: a retrospective cohort studyAging Male2026 Dec 31PMID 41879268
- Clinical and economic value of onabotulinumtoxinA vs oral pharmacotherapies in overactive bladder in the United StatesJ Med Econ2026 DecPMID 42768867
- Management of Urinary Symptoms in Multiple Sclerosis: An Umbrella ReviewNeurourol Urodyn2026 Oct 16PMID 42885333Review
- The combined medication approach for treating overactive bladder: assessing safety and efficacyBr J Nurs2026 Oct 8PMID 42848697Review
- A Modular Synthesis of C5-Sulfenyl Thiazoles via an Intermolecular Pummerer Rearrangement: An Underexplored Scaffold for Medicinal ChemistryAngew Chem Int Ed Engl2026 Oct 5PMID 42604554
- Efficacy and safety of mirabegron for the treatment of bladder dysfunction in the pediatric population: A prospective observational studyActas Urol Esp (Engl Ed)2026 OctPMID 42413610
- Vibegron, mirabegron, and other add-on therapies for persistent overactive bladder symptoms in α1-blocker-treated men with benign prostatic hyperplasia: a systematic review and Bayesian network meta-analysisWorld J Urol2026 Sep 28PMID 42803972Systematic review
- Clinical efficacy of bladder hydrodistension combined with oral mirabegron and intravesical instillation in the treatment of interstitial cystitisPak J Med Sci2026 SepPMID 42818942
- [Urinary incontinence caused by an overactive bladder]Rev Prat2026 SepPMID 42808615Review
- Efficacy of Vibegron in Overactive Bladder: A Bayesian Cross-Trial Synthesis of Benefit Probabilities and Decision ThresholdsLow Urin Tract Symptoms2026 SepPMID 42665534
More urology trends
All specialties →PSMA PET in prostate cancer
PSMA PET imaging for staging and recurrence of prostate cancer.
Key point: PSMA-PET/CT is recommended only when PSA exceeds 0.2 μg/L, reporting should follow PSMA-RADS, and it is preferred over lymph-node dissection for staging.
Male infertility
Male infertility and trends in semen quality.
Key point: Male infertility management should be couple-centered, integrating the female partner's reproductive timeline to avoid preventable delays in effective therapy.
Robotic partial nephrectomy
Robot-assisted partial nephrectomy for kidney tumours.
Focal therapy for prostate cancer
Treating only the tumour area within the prostate.
BCG-unresponsive bladder cancer
New options for non-muscle invasive bladder cancer after BCG fails.
Preventing recurrent UTIs
Vaccines and non-antibiotic prevention of recurrent urinary tract infections.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
vibegron[tiab] OR mirabegron[tiab]Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.